현재가
목표 주가
Jupiter Neurosciences, Inc., a clinical stage research and development pharmaceutical company, develops resveratrol platform products primarily for the treatment of neuroinflammation. The company is headquartered in Jupi...|
e.g. Promoter holding
Loading chart...
애널리스트 컨센서스 기준 EPS 및 매출 전망.
| Metric (B) | FY 2025 | FY 2025 | FY 2026 | FY 2026 | FY 2026 |
|---|---|---|---|---|---|
| $-0.08 | $-0.26 | $-0.05 | $0.06 | $0.06 | |
| 0 | 0 | 0 | 0.01 | 0.01 | |
| -14.3% | -4.0% | -25.0% | -45.5% | -45.5% |
| S.No. | Name | Symbol | Market Cap | P/E | P/B | Profit Margin | Op. Margin | ROE | Rev. Growth |
|---|---|---|---|---|---|---|---|---|---|
| 1. | NNeuroSense... | NRSN | $3.21M | — | 2.64 | — | — | -2,175.00% | — |
| 2. | RReviva Pha... | RVPHW | $85.81M | — | — | — | — | -916.00% | — |
| 3. | BBioCardia... | BCDA | $12.58M | — | 15.07 | — | — | -1,803.00% | -100.00% |
| 4. | OOS Therapi... | OSTX | $34.87M | — | 12.74 | — | — | -914.00% | — |
| 5. | OOS Therapi... | OSTX | $34.87M | — | 12.74 | — | — | -914.00% | — |
연결 기준 (백만 단위) / 별도 보기 가능
| Quarter (M) | Sep 24 | Dec 24 | Mar 25 | Jun 25 | Sep 25 | Dec 25 | Mar 26 | Jun 26 |
|---|---|---|---|---|---|---|---|---|
Revenue | 0 | 0 | 0 | 0 | 0 | 0.02 | 0.02 | 0.02 |
COGS | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 | 0 | 0.02 | 0.02 |
Gross Profit % | - | - | - | - | - | - | 100% | 86.88% |
| 0.49 | 1.46 | 1.54 | 2.26 | 2.3 | 2.83 | 2.83 | 2.76 | |
EBIT | -0.49 | -1.46 | -1.54 | -2.26 | -2.3 | -2.81 | -2.81 | -2.74 |
OPM % | - | - | - | - | - | -12886.7% | -12886.7% | -11313.45% |
Non-Operating Income | -0.1 | -0.07 | 0.01 | 0.01 | 0.01 | 0.23 | 0.23 | 0.47 |
PBT | -0.59 | -1.53 | -1.53 | -2.25 | -2.29 | -2.58 | -2.58 | -2.27 |
Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Tax Rate % | - | - | - | - | - | - | - | - |
Net Income | -0.59 | -1.53 | -1.53 | -2.25 | -2.29 | -2.58 | -2.58 | -2.27 |
NPM % | - | - | - | - | - | -11814.24% | -11814.24% | -9380.89% |
연결 기준 (백만 단위) / 별도 보기 가능
| Period (M) | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
Revenue | 0 | 1.13 | 0.64 | 0.23 | 0 | 0 | 0.02 |
COGS | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 1.13 | 0.64 | 0.23 | 0 | 0 | 0.02 |
Gross Profit % | - | 100% | 100% | 100% | - | - | 80.59% |
| 2.18 | 2.98 | 4.55 | 3.67 | 3.87 | 3.09 | 8.93 | |
EBIT | -2.18 | -1.85 | -3.91 | -3.43 | -3.87 | -3.09 | -8.91 |
OPM % | - | -164.41% | -612.36% | -1471.38% | - | - | -40873.19% |
Non-Operating Income | 0 | 0.2 | -0.29 | -1.53 | -0.91 | 0.65 | 0.26 |
PBT | -3.05 | -1.65 | -4.2 | -4.96 | -4.78 | -2.44 | -8.64 |
Income Tax | 0 | 0 | 0.18 | 0 | 0 | 0 | 0 |
Tax Rate % | - | - | -4.27% | - | - | - | - |
Net Income | -3.05 | -1.65 | -4.38 | -4.96 | -4.78 | -2.44 | -8.64 |
NPM % | - | -146.92% | -686.39% | -2125.15% | - | - | -39662.77% |
연결 기준 (백만 단위) / 별도 보기 가능
| Period (M) | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| 0 | 0.21 | 0.33 | 0.06 | 0.03 | 3.77 | 3.79 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| 0 | 0.34 | 0.12 | 0.01 | 0 | 0.88 | 1.04 | |
| 0 | 0 | 0.21 | 0.17 | 0.12 | 1.55 | 0.74 | |
Total Assets | 0.01 | 0.55 | 0.67 | 0.24 | 0.15 | 6.2 | 5.56 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| -5.02 | -3.71 | -5.18 | -7.15 | -5.8 | 4.17 | -1.84 | |
| 1.21 | 0.11 | 0.65 | 1.9 | 2.25 | 0.22 | 5.32 | |
| 3.81 | 4.15 | 5.19 | 5.48 | 3.7 | 1.81 | 2.21 | |
| 0 | 0 | 0 | 0 | -0 | 0 | -0.13 | |
Total Liabilities | 0.01 | 0.55 | 0.67 | 0.24 | 0.15 | 6.2 | 5.56 |
연결 기준 (백만 단위) / 별도 보기 가능
| Period (M) | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| -0.14 | -0.25 | -1.74 | -1.25 | -0.48 | -3.91 | -5.41 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| 0.11 | 0.46 | 1.86 | 0.98 | 0.45 | 7.65 | 5.43 | |
Net CFNet Cash Flow | -0.04 | 0.21 | 0.12 | -0.27 | -0.04 | 3.74 | 0.02 |
FCFFree Cash Flow | -0.14 | -0.25 | -1.74 | -1.25 | -0.48 | -3.91 | -5.41 |
Financial ratios and valuation metrics by fiscal year.
| Period | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| - | 37.9% | 98.5% | 80.5% | 73.9% | 299.5% | -738.8% | |
| -0.24 | -0.03 | -0.13 | -0.27 | -0.39 | 0.05 | -2.90 | |
| 0.00 | 0.13 | 0.08 | 0.01 | 0.00 | 2.31 | 0.65 | |
| - | 4.05 | 1.05 | 0.52 | 0.00 | 0.00 | 0.00 | |
Cash Conversion | 0.05 | 0.15 | 0.40 | 0.25 | 0.10 | 1.60 | 0.63 |
Payout Ratio | - | - | - | - | - | - | - |
| - | - | -43.3% | -63.4% | -100.0% | - | - | |
| - | - | - | - | - | - | - | |
| - | - | - | - | - | - | - | |
| 3.00 | 4.00 | 2.00 | 3.00 | 1.00 | 3.00 | 3.00 | |
| - | - | -22.66 | -77.16 | - | - | - | |
| - | 100.00 | 100.00 | 100.00 | - | 50.00 | 100.00 | |
| - | -1.5% | -6.9% | -21.3% | - | - | -396.6% |
Note: These ratios and scores are calculated using publicly available financial data and may differ from other sources. Users are advised to verify calculations independently using SEC filings or other official sources before making investment decisions.
Jupiter Neurosciences Inc의 주주 구성 (SEC 공시 기준)
이 회사의 SEC 지분 공시가 아직 없습니다.
Jupiter Neurosciences Inc의 SEC 공시 및 실적 발표 컨퍼런스콜 녹취록
이 회사의 SEC 공시가 아직 없습니다.
What recent news says about Jupiter Neurosciences Inc, scored for sentiment.